In this context, it appears that the preponderant treatment modality applied to HR+ BC, which consists in the administration of estrogen receptor antagonist or that of aromatase inhibitors, has profound effects on immune cells (which express estrogen receptors), meaning that (part of) their therapeutic efficacy may transcend the cancer cell-autonomous action of such hormone therapies. Here, CYP19A1 is linked to cancer.